151 studies (12 from unattributed sources) on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Hk Peptides | 139 | 99.77% | View COA → |
| Lilipeptide | 135 | 99.56% | View COA → |
| Shanghai Sigma Audley Ssa | 126 | 99.45% | View COA → |
| Qing Li Peptide | 118 | 99.62% | View COA → |
| Unknown vendor (review) | 117 | 99.79% | View COA → |
| Nexaph | 115 | 99.41% | View COA → |
| Bfflist Amo | 105 | 99.71% | View COA → |
| Peptaris | 105 | 99.29% | View COA → |
Recent certificates: #26981 (99.69%) · #26982 (99.91%) · #27579 (99.87%) · #30753 (99.94%) · #38586 (99.75%) · #42718 (99.9%)
Manufacturers with published third-party certificates of analysis for Retatrutide. Open a vendor to see every batch we've verified.
This review underscores the critical need for integrated care models that combine pharmacological treatment with tailored nutritional guidance. Implementing personalized dietary plans alongside AOMs could significantl…
Free, no account — handy when you're working with Retatrutide.